{"id":1913,"date":"2024-12-21T16:57:10","date_gmt":"2024-12-21T13:57:10","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=1913"},"modified":"2025-06-21T13:49:54","modified_gmt":"2025-06-21T10:49:54","slug":"uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment\/","title":{"rendered":"Le Royaume-Uni approuve le Givinostat (Duvyzat) pour le traitement de la dystrophie musculaire de Duchenne"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This approval, announced on 20 December 2024, marks a crucial step forward in the treatment of this debilitating genetic disorder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Givinostat is a nonsteroidal drug indicated for the treatment of patients aged 6 years of age and older with all genetic variants of DMD. [Read more: <a href=\"https:\/\/dmdwarrior.com\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" data-type=\"post\" data-id=\"1462\" rel=\"noreferrer noopener\">What is Duvyzat (Givinostat)?<\/a>]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD). In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat. This approval, announced on 20 December 2024, marks a crucial step [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1916,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[46,49,47,50,48],"class_list":["post-1913","post","type-post","status-publish","format-standard","has-post-thumbnail","category-approved-therapies-for-duchenne-muscular-dystrophy","tag-duvyzat","tag-england","tag-givinostat","tag-mhra","tag-uk"],"subtitle":"L'approbation conditionnelle de la MHRA permet l'utilisation du givinostat chez les patients atteints de DMD \u00e2g\u00e9s de six ans et plus, et elle est applicable \u00e0 toutes les variantes g\u00e9n\u00e9tiques de la maladie. Cette d\u00e9cision fait suite \u00e0 l'approbation du givinostat par la Food and Drug Administration (FDA) des \u00c9tats-Unis plus t\u00f4t cette ann\u00e9e.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/1913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=1913"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/1913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/1916"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=1913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=1913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=1913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}